Patient-Derived Gastric Cancer Assembloids Reveal Stromal Impact on Drug Response

Study Background and Research Question

Gastric cancer remains a formidable clinical challenge, ranking among the top five most diagnosed cancers globally and contributing significantly to cancer-related mortality. Despite advances in surgery, chemotherapy, and targeted therapies, the five-year survival rate for advanced cases remains below 10%, largely due to pronounced tumor heterogeneity and therapy resistance. Traditional three-dimensional tumor models—such as monoculture organoids—have provided valuable insights into epithelial cancer cell biology but often fail to capture the full complexity of the tumor microenvironment, especially the diverse stromal cell populations implicated in drug resistance and disease progression. The primary aim of the referenced study (Shapira-Netanelov et al., 2025) was to develop a more physiologically relevant in vitro model that better recapitulates the cellular heterogeneity and microenvironmental context of patient tumors, enabling improved drug response prediction and mechanistic exploration.

Key Innovation from the Reference Study

The central innovation of this study is the creation of a "gastric cancer assembloid" system that integrates patient-derived tumor organoids with autologous stromal subpopulations—specifically, mesenchymal stem cells, fibroblasts, and endothelial cells—all isolated from the same tumor specimen. Unlike conventional organoid cultures, which lack supporting stromal elements, these assembloids preserve native tumor-stroma interactions, more closely mirroring the cellular and molecular diversity of primary gastric tumors. This approach enables direct investigation of how stromal components contribute to gene expression profiles, tumor progression, and—crucially—modulate drug sensitivity and resistance mechanisms (Shapira-Netanelov et al., 2025).

Methods and Experimental Design Insights

The authors employed a systematic protocol to dissociate primary gastric tumor tissue and expand distinct cell populations using tailored culture conditions. Epithelial tumor organoids, mesenchymal stem cells, fibroblasts, and endothelial cells were individually propagated in optimized media to retain their respective phenotypes. These matched populations were then recombined in a defined assembloid medium, supporting the co-culture of all subtypes. The resulting assembloids were characterized by immunofluorescence staining for lineage-specific markers and by transcriptomic profiling using RNA sequencing to assess cellular composition and gene expression dynamics. Drug responsiveness was evaluated through cell viability assays following treatment with various therapeutic agents, enabling comparison of drug sensitivity between monoculture organoids and more complex assembloid models.

Protocol Parameters

• Tissue dissociation: Enzymatic and mechanical dissociation of fresh gastric tumor tissue to yield single-cell suspensions for lineage-specific expansion.
• Organoid culture: Tumor epithelial cells expanded in Matrigel-based 3D culture with growth factors tailored for gastric epithelium.
• Stromal subpopulation expansion: Mesenchymal, fibroblast, and endothelial lineages maintained in lineage-appropriate media to retain phenotype and viability.
• Assembloid formation: Recombination of tumor organoids with matched stromal cells in an optimized co-culture medium, supporting all populations.
• Immunofluorescence and RNA-seq: Marker-based validation and transcriptomic analysis to confirm cell identities and profile gene expression.
• Drug screening: Cell viability measured after exposure to chemotherapeutic and targeted agents; sensitivity compared between organoid and assembloid formats.

Core Findings and Why They Matter

The assembled gastric cancer models demonstrated several critical advances. First, assembloids exhibited a cellular composition and marker expression profile closely resembling the primary tumor, confirming the successful recapitulation of intra-tumoral heterogeneity. Second, transcriptomic analysis revealed that co-culture with autologous stromal populations led to upregulation of inflammatory cytokines, extracellular matrix remodeling enzymes, and tumor progression-associated genes—features often missing in monoculture organoids. Most importantly, drug response assays uncovered pronounced differences in sensitivity: some agents retained efficacy in both organoid and assembloid systems, while others were significantly less effective in the presence of stromal components. This attenuation of drug response underscores the pivotal role of the tumor stroma in shaping therapeutic outcomes and highlights the limitations of monoculture models for preclinical drug screening. By providing a platform that captures these physiologically relevant interactions, this assembloid approach enhances the predictive power of in vitro models for personalized oncology research (Shapira-Netanelov et al., 2025).

Comparison with Existing Internal Articles

Several recent analyses have explored the integration of fluoropyrimidine prodrugs, such as Capecitabine (N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine), within advanced tumor–stroma model systems. For instance, the article "Capecitabine in Tumor-Stromal Models: Enhancing Chemotherapy Selectivity" details how the stromal context modulates Capecitabine activation and apoptosis induction via Fas-dependent pathways, echoing the reference study's emphasis on stromal influence. Similarly, "Capecitabine in Advanced Tumor Microenvironment Modeling" highlights the importance of tumor-targeted drug delivery and the value of assembloid models in dissecting resistance mechanisms. These internal resources reinforce the conclusion that physiologically relevant co-culture systems are essential for accurate drug efficacy assessment and for understanding the complex interplay between tumor and stromal cells in preclinical oncology research. The reference study extends these themes to gastric cancer, providing an actionable framework for translational research and precision drug screening.

Limitations and Transferability

While the gastric cancer assembloid model marks substantial progress toward more predictive in vitro platforms, several limitations merit consideration. The creation of patient-matched stromal and epithelial populations is labor-intensive and may not be scalable for high-throughput screening or for all tumor types. Additionally, the current model, while incorporating key stromal elements, does not yet capture the full spectrum of immune or neural components present in vivo. Drug responses observed in assembloids may still diverge from clinical outcomes due to the absence of systemic pharmacokinetics and multi-organ interactions. Nonetheless, the framework is highly adaptable and offers a direct route to investigating resistance mechanisms and biomarker discovery in the context of personalized medicine, especially for cancers with high stromal content such as gastric and colon carcinomas.

Research Support Resources

Researchers aiming to model tumor–stroma interactions and evaluate drug responses in assembloid systems may benefit from using well-characterized compounds such as Capecitabine (SKU A8647), a fluoropyrimidine prodrug widely used in preclinical oncology research. Capecitabine's tumor-selective activation and its apoptosis induction via Fas-dependent pathways make it particularly suitable for studies focused on tumor-targeted drug delivery and resistance mechanisms. Product information—including purity, solubility, and protocol suggestions—can be consulted for workflow optimization. For further background on Capecitabine’s utility in assembloid and microenvironmental models, see the internal review "Capecitabine: Fluoropyrimidine Prodrug in Advanced Oncology Models".